Favourable safety and tolerability profile, high treatment compliance and encouraging efficacy signals sustained through one-month follow-up support continued development of RESP303 in chronic respiratory infections.

A big congratulations to the Convatec team on the regulatory approval of ConvaNiox – a major milestone for nitric oxide-based wound care.

30 Technology is excited to announce that on October 16, 2024, the first patient was enrolled into the NOPA study.